development aspects
Moderna Revamps R&D Strategy with $1.1B Cuts and Pipeline Overhaul
Moderna, R&D cuts, pipeline overhaul, biotechnology, pharmaceutical industry, cost reduction, research and development.
Vaxcyte Announces Positive Phase 1/2 Results for VAX-31, Advances to Phase 3
Vaxcyte, VAX-31, pneumococcal conjugate vaccine, Phase 1/2 study, Phase 3 program, vaccine development, bacterial diseases
Pfizer and Valneva Announce Positive Phase 2 Results for Lyme Disease Vaccine Candidate VLA15
Lyme disease, VLA15, Pfizer, Valneva, vaccine development, tick-borne diseases
Vaxcyte Advances 31-Valent Pneumococcal Vaccine to Phase 3 Trials Following Positive Phase 1/2 Results
Vaxcyte, VAX-31, Pneumococcal Vaccine, Phase 3 Trials, Invasive Pneumococcal Disease, Vaccine Development
UCLA Receives $120 Million Donation for Immunology Research and Vaccine Development
UCLA, immunology research, vaccine development, $120 million donation, Gary Michelson, Alya Michelson, California Institute for Immunology and Immunotherapy
BioMarin Appoints New R&D and Business Development Leaders
BioMarin, R&D, Business Development, Leadership, Greg Friberg, James Sabry, Hank Fuchs
Arrowhead Shifts Focus to Obesity Development After Heart Disease Drug Clearance
Arrowhead, obesity development, heart disease drug, biotech, pharmaceuticals, clinical-stage candidates, preclinical assets
Evotec Announces 400 Job Cuts Amid Market Challenges
Evotec, job cuts, market challenges, restructuring, drug discovery, contract development, manufacturing
Lilly Opens State-of-the-Art Research and Development Center in Boston
Lilly, Boston, research and development, genetics research, biotech incubator, East Coast hub
Aeterna Zentaris Rebrands as COSCIENS Biopharma: A New Era in Biopharmaceuticals
Aeterna Zentaris, COSCIENS Biopharma, biopharmaceuticals, rebranding, name change, therapeutic development, diagnostic tests, Macrilen, adult growth hormone deficiency